A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell [CAR-T] Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (NCT07391657)

A Phase III, Open-label, Randomised, Multicentre Study Comparing AZD0120 (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma.

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Dr Sueh-Li Lim

Key inclusion data

Must have received 1 to 3 lines of prior therapy including an IMiD and either a PI or an anti-CD38 antibody. Cannot have known active, or prior history of CNS involvement or exhibit clinical signs of meningeal involvement of MM. Cannot have active plasma cell leukaemia at time of screening. Cannot have primary refractory MM (failed to generate at least a minimal response to any prior therapy).